K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine
about
Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitroAntiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strainsDrug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization.Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaquesHigh prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD).Computational model of hepatitis B virus DNA polymerase: molecular dynamics and docking to understand resistant mutations.In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue.A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection.The kissing hairpin sequence promotes recombination within the HIV-I 5' leader region.An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.
P2860
Q28378896-DBCAF4CD-DC43-415F-94FB-7EDA60682D63Q28379249-BBFB914B-DACB-4A34-8154-E9C90A93F3DDQ28379552-0027AA7F-0369-4745-A65D-DA21C1C77FD0Q31430709-9926D29B-80A8-4AAB-9B26-CD02D824515CQ33782538-9440CD63-C7C0-4549-954B-5088A9508D1FQ34465037-67DFF8F3-58EE-4F1D-BB21-5A846FE5A179Q35129347-9A3CBA49-69B9-4DB5-A61E-782118780DAAQ35215399-A6B38F55-B0DF-4481-8036-81ACFF3D8F92Q37387866-713DC67D-92D0-4203-A703-646829819FC5Q37708188-16F24FD8-5552-49CC-979F-35DD6F37D9EFQ39557921-98B1BB65-A780-4FF7-B63C-AE62DD83D363Q39651695-B47159C4-315A-4214-BC27-7C6DD0E5D3F5Q40128143-839BC211-3F61-4A5E-A990-F250E88A8C27Q40454877-F69788B5-DA33-4D81-8A06-D5B090E17F45Q40902737-9A256FD8-9D99-4EBF-B0DE-271B1B0BE6EAQ41892773-EEA4A860-A546-49E5-AE5E-3A87FF2F4AF8Q44916253-E0CD51D8-5E42-4BBF-8865-8F12B3C48717Q45745544-8B3878CE-EF40-4AAC-9181-EF60465E1406Q52543360-F34850B4-62AE-4301-8811-21AD39775293Q55340159-D213D4C9-BF3A-4C7D-8BF1-40AB22CCBB14
P2860
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
K65R mutation of human immunod ...... phosphonylmethoxyethyl)adenine
@ast
K65R mutation of human immunod ...... phosphonylmethoxyethyl)adenine
@en
K65R mutation of human immunod ...... phosphonylmethoxyethyl)adenine
@nl
type
label
K65R mutation of human immunod ...... phosphonylmethoxyethyl)adenine
@ast
K65R mutation of human immunod ...... phosphonylmethoxyethyl)adenine
@en
K65R mutation of human immunod ...... phosphonylmethoxyethyl)adenine
@nl
prefLabel
K65R mutation of human immunod ...... phosphonylmethoxyethyl)adenine
@ast
K65R mutation of human immunod ...... phosphonylmethoxyethyl)adenine
@en
K65R mutation of human immunod ...... phosphonylmethoxyethyl)adenine
@nl
P2093
P2860
P356
P1476
K65R mutation of human immunod ...... phosphonylmethoxyethyl)adenine
@en
P2093
A S Mulato
J M Cherrington
K M Sogocio
M A Wainberg
R Yarchoan
P2860
P304
P356
10.1128/AAC.39.8.1888
P407
P577
1995-08-01T00:00:00Z